BFA
SLNO

BlackRock Fund Advisors’s Soleno Therapeutics SLNO Stock Holding History

BlackRock Fund Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1K Buy
21
+7
+50% +$485 ﹤0.01% 4195
2016
Q3 		$1K Buy
14
+2
+17% +$152 ﹤0.01% 4223
2016
Q2 		$1K Buy
12
+1
+9% +$91 ﹤0.01% 4281
2016
Q1 		$1K Buy
+11
New +$1.08K ﹤0.01% 4285

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock Fund Advisors's SLNO Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Soleno Therapeutics (SLNO) stake by 50% in Q4 2016, buying an estimated $485 and bringing the position to 21 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #4195.

BlackRock Fund Advisors first reported a position in SLNO in Q1 2016 and has held it in 4 quarters since. 12 funds tracked by Wall St. Rank hold SLNO as of Q4 2016.

  • BlackRock Fund Advisors held 21 shares of Soleno Therapeutics worth $1K as of Q4 2016.
  • BlackRock Fund Advisors bought 7 Soleno Therapeutics shares in Q4 2016, an estimated $485.
  • Soleno Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #4195 holding.
  • BlackRock Fund Advisors first reported a position in Soleno Therapeutics in Q1 2016 and has held it in 4 quarters since.
  • 12 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.